SG10201914019YA - Antibody producing non-human mammals - Google Patents

Antibody producing non-human mammals

Info

Publication number
SG10201914019YA
SG10201914019YA SG10201914019YA SG10201914019YA SG10201914019YA SG 10201914019Y A SG10201914019Y A SG 10201914019YA SG 10201914019Y A SG10201914019Y A SG 10201914019YA SG 10201914019Y A SG10201914019Y A SG 10201914019YA SG 10201914019Y A SG10201914019Y A SG 10201914019YA
Authority
SG
Singapore
Prior art keywords
human mammals
antibody producing
producing non
mammals
antibody
Prior art date
Application number
SG10201914019YA
Other languages
English (en)
Inventor
Erwin Houtzager
Rui Daniel Pinto
Ton Logtenberg
Mark Throsby
Robert Kramer
Kruif Cornelis De
Original Assignee
Merus Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41280336&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201914019Y(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merus Nv filed Critical Merus Nv
Publication of SG10201914019YA publication Critical patent/SG10201914019YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Environmental Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Husbandry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG10201914019YA 2008-06-27 2009-06-29 Antibody producing non-human mammals SG10201914019YA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL2008050430 2008-06-27

Publications (1)

Publication Number Publication Date
SG10201914019YA true SG10201914019YA (en) 2020-03-30

Family

ID=41280336

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201408500RA SG10201408500RA (en) 2008-06-27 2009-06-29 Antibody producing non-human mammals
SG10201914019YA SG10201914019YA (en) 2008-06-27 2009-06-29 Antibody producing non-human mammals
SG10201914027VA SG10201914027VA (en) 2008-06-27 2009-06-29 Antibody producing non-human mammals

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201408500RA SG10201408500RA (en) 2008-06-27 2009-06-29 Antibody producing non-human mammals

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201914027VA SG10201914027VA (en) 2008-06-27 2009-06-29 Antibody producing non-human mammals

Country Status (23)

Country Link
EP (6) EP3456191A1 (de)
JP (6) JP5749161B2 (de)
KR (5) KR20110029156A (de)
CN (3) CN105191863B (de)
AU (1) AU2009263082C1 (de)
CA (1) CA2729095C (de)
CY (2) CY1114830T1 (de)
DK (3) DK3456190T3 (de)
ES (3) ES2445193T3 (de)
HK (1) HK1154463A1 (de)
HR (2) HRP20220205T1 (de)
HU (1) HUE057994T2 (de)
LT (1) LT3456190T (de)
MX (1) MX2010014542A (de)
NZ (1) NZ590118A (de)
PL (2) PL3456190T3 (de)
PT (3) PT3456190T (de)
RS (2) RS62925B1 (de)
RU (2) RU2731084C2 (de)
SG (3) SG10201408500RA (de)
SI (2) SI3456190T1 (de)
WO (1) WO2009157771A2 (de)
ZA (1) ZA201009312B (de)

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
PT1523496E (pt) 2002-07-18 2011-09-29 Merus B V Produção de misturas de anticorpos de forma recombinante
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
WO2004106375A1 (en) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
GB2404382B (en) 2003-07-28 2008-01-30 Oxitec Ltd Pest control
GB2443186A (en) 2006-10-25 2008-04-30 Oxitec Ltd Expression system for mediating alternative splicing
KR20110029156A (ko) * 2008-06-27 2011-03-22 메뤼스 베.페. 항체 생산 비-인간 포유동물
PL2346994T3 (pl) 2008-09-30 2022-04-19 Ablexis, Llc Myszy knock-in do wytwarzania chimerycznych przeciwciał
HUE055817T2 (hu) 2009-07-08 2021-12-28 Kymab Ltd Állatmodellek és terápiás molekulák
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
AU2013204019B2 (en) * 2010-02-08 2014-02-27 Regeneron Pharmaceuticals, Inc. Common light chain mouse
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US20120021409A1 (en) * 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
NZ719253A (en) * 2010-02-08 2022-08-26 Regeneron Pharma Common light chain mouse
CA3006800C (en) 2010-03-31 2022-10-04 Ablexis, Llc Genetic engineering of non-human animals for the production of chimeric antibodies
EP2582230A1 (de) * 2010-06-17 2013-04-24 Kymab Limited Tiermodelle und therapeutische moleküle
US10793829B2 (en) 2010-07-26 2020-10-06 Trianni, Inc. Transgenic mammals and methods of use thereof
JP6482757B2 (ja) 2010-07-26 2019-03-13 トリアンニ インコーポレイテッドＴｒｉａｎｎｉ，Ｉｎｃ． トランスジェニック動物および使用方法
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
EP3960865A1 (de) * 2010-08-02 2022-03-02 Regeneron Pharmaceuticals, Inc. Mäuse, die bindeproteine mit vl-domänen produzieren
SG2014007686A (en) 2011-08-05 2014-03-28 Regeneron Pharma Humanized universal light chain mice
CN103945689B (zh) 2011-09-19 2016-10-19 科马布有限公司 免疫球蛋白基因多样性的操纵及多抗体治疗剂
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
SG10201805622QA (en) * 2011-12-22 2018-08-30 Hoffmann La Roche Expression Vector Organization, Novel Production Cell Generation Methods And Their Use For The Recombinant Production Of Polypeptides
DK3597038T3 (da) * 2012-02-01 2021-06-28 Regeneron Pharma Humaniserede gnavere, der udtrykker tungkæder indeholdende VL-domæner
GB2500113A (en) 2012-03-05 2013-09-11 Oxitec Ltd Arthropod male germline gene expression system
SG11201405088QA (en) * 2012-03-06 2014-11-27 Regeneron Pharma Common light chain mouse
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
RS57414B1 (sr) 2012-03-16 2018-09-28 Regeneron Pharma Antitela sa lakim lancem konstruisanim sa histidinom i genetički modifikovani glodari za generisanje istih
CA2865644A1 (en) 2012-03-16 2013-09-19 Regeneron Pharmaceuticals, Inc. Mice that produce antigen-binding proteins with ph-dependent binding characteristics
NZ712508A (en) 2012-03-16 2018-06-29 Regeneron Pharma Non-human animals expressing ph-sensitive immunoglobulin sequences
GB2502127A (en) * 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
SI2838918T1 (sl) 2012-04-20 2019-11-29 Merus Nv Postopki in sredstva za proizvodnjo heterodimernih IG-podobnih molekul
SG11201407644UA (en) * 2012-06-05 2014-12-30 Regeneron Pharma Methods for making fully human bispecific antibodies using a common light chain
EP2869845B1 (de) 2012-07-06 2019-08-28 Genmab B.V. Dimerprotein mit dreifacher mutation
CN103571872B (zh) * 2012-08-09 2016-11-23 山东国际生物科技园发展有限公司 一种能够表达人抗体的转基因动物的制备方法
SG10201705787VA (en) 2012-09-27 2017-08-30 Merus Nv BISPECIFIC IgG ANTIBODIES AS T CELL ENGAGERS
GB201303932D0 (en) 2013-03-05 2013-04-17 Oxitec Ltd Muscle actin promoter
FI3501272T3 (fi) * 2013-03-13 2023-04-06 Regeneron Pharma Rajallista immunoglobuliinin kevytketjuvalikoimaa ilmentäviä hiiriä
PT2968440T (pt) 2013-03-15 2019-07-31 Zymeworks Inc Compostos citotóxicos e antimitóticos e métodos de utilização dos mesmos
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
SG10201802295XA (en) 2013-10-01 2018-04-27 Kymab Ltd Animal Models and Therapeutic Molecules
CA2926090C (en) * 2013-10-15 2022-07-05 Regeneron Pharmaceuticals, Inc. Humanized il-15 animals
EP3086815B1 (de) 2013-12-27 2022-02-09 Zymeworks Inc. Sulfonamidhaltige verknüpfungssysteme für arzneimittelkonjugate
CA2941030A1 (en) 2014-02-28 2015-09-03 Merus N.V. Antibodies that bind egfr and erbb3
MX2016011155A (es) 2014-02-28 2017-02-22 Merus Nv Anticuerpo que une erbb-2 y erbb-3.
WO2015143414A2 (en) 2014-03-21 2015-09-24 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
EP3119811B1 (de) 2014-03-21 2019-10-30 Regeneron Pharmaceuticals, Inc. Vl antigen-bindende proteine mit unterschiedlichen bindungseigenschaften
GB2526867A (en) * 2014-06-05 2015-12-09 Oxitec Ltd Gene expression system
EP3194421B1 (de) 2014-09-17 2021-11-03 Zymeworks Inc. Cytotoxische und antimitotische verbindungen und verfahren zur verwendung davon
CN107438622A (zh) 2015-03-19 2017-12-05 瑞泽恩制药公司 选择结合抗原的轻链可变区的非人动物
SI3115376T1 (sl) 2015-07-10 2018-12-31 Merus N.V. Humana protitelesa, ki vežejo CD3
KR20180038055A (ko) 2015-08-24 2018-04-13 트리아니, 인코포레이티드 면역글로불린의 강화된 생산
CN108602888B (zh) 2015-10-23 2022-10-04 美勒斯公司 抑制癌症生长的结合分子
EP3384030A4 (de) 2015-12-03 2019-07-03 Trianni, Inc. Verbesserte immunglobulindiversität
US11053288B2 (en) 2016-02-04 2021-07-06 Trianni, Inc. Enhanced production of immunoglobulins
CN116458475A (zh) 2016-06-03 2023-07-21 瑞泽恩制药公司 表达外源末端脱氧核苷酸转移酶的非人动物
WO2018029534A1 (en) 2016-08-12 2018-02-15 Oxitec Ltd. A self-limiting, sex-specific gene and methods of using
NZ751956A (en) 2016-09-23 2022-01-28 Merus Nv Binding molecules that modulate a biological activity expressed by a cell
EP3601528A4 (de) * 2017-03-20 2021-05-05 Washington University Zellen und verfahren zur verwendung und herstellung derselben
MX2019011658A (es) 2017-03-31 2019-11-18 Merus Nv Agente que se dirige al receptor 2 del factor de crecimiento epidermico humano (erbb-2) y anticuerpo biespecifico con sitios de union a antigeno que se unen a un epitopo sobre una parte extracelular de erbb-2 y el receptor 3 del factor de crecimiento epidermico humano (erbb-3), para el tratamiento de un individuo con un tumor positivo para erbb-2, erbb-2/erbb-3.
MX2019011660A (es) 2017-03-31 2019-11-18 Merus Nv Anticuerpos biespecificos que se unen al receptor 2 del factor de crecimiento humano (erbb-2) y receptor 3 del factor de crecimiento humano (erbb3) para usarse en el tratamiento de celulas que tienen un gen de fusion de neuregulina-1 (nrg1).
ES2951864T3 (es) 2017-05-17 2023-10-25 Merus Nv Combinación de un anticuerpo biespecífico ERBB-2/ERBB-3 con terapia endocrina para el cáncer de mama
EP3649155A1 (de) 2017-07-06 2020-05-13 Merus N.V. Bispezifische anti-pd1-anti-tim3-antikörper
CA3068933A1 (en) 2017-07-06 2019-01-10 Merus N.V. Antibodies that modulate a biological activity expressed by a cell
EA202090003A1 (ru) 2017-07-06 2020-06-18 Мерус Н.В. Связывающие молекулы, модулирующие биологическую активность, которую проявляет клетка
GB201710984D0 (en) * 2017-07-07 2017-08-23 Kymab Ltd Cells, vertebrates, populations & methods
MA49846A (fr) 2017-08-09 2020-06-17 Merus Nv Anticorps qui se lient à l'egfr et à cmet
WO2019108065A1 (en) 2017-12-01 2019-06-06 Merus N.V. Use of bispecific antibody and il-15 for combination therapy
AU2018381316A1 (en) * 2017-12-05 2020-04-23 Regeneron Pharmaceuticals, Inc. Non-human animals having an engineered immunoglobulin lambda light chain and uses thereof
TWI804572B (zh) 2018-02-09 2023-06-11 日商小野藥品工業股份有限公司 雙特異性抗體
TWI842701B (zh) 2018-03-24 2024-05-21 美商再生元醫藥公司 用於產生抗肽-mhc複合物之治療性抗體的經基因修飾的非人類動物、其製法與用途
US11952424B2 (en) 2018-03-30 2024-04-09 Merus N.V. Multivalent antibody
CN108624622A (zh) * 2018-05-16 2018-10-09 湖南艾佳生物科技股份有限公司 一种基于CRISPR-Cas9系统构建的能分泌小鼠白细胞介素-6的基因工程细胞株
JP7269963B2 (ja) * 2018-06-08 2023-05-09 クリスタル バイオサイエンス インコーポレイテッド 同じ軽鎖ｉを有する多様な抗体を産生するためのトランスジェニック動物
KR102444180B1 (ko) 2018-06-14 2022-09-16 리제너론 파마슈티칼스 인코포레이티드 면역글로불린 중쇄 암호화 서열에서 dh-dh 재배열 가능한 비인간 동물
MA54525A (fr) 2018-12-20 2021-10-27 Merus Nv Anticorps bispécifiques clec12axcd3 et méthodes de traitement d'une maladie
EP3897117A1 (de) 2018-12-21 2021-10-27 Compass Therapeutics LLC Transgene maus, die eine gemeinsame menschliche leichte kette exprimiert
MX2021007949A (es) 2018-12-31 2021-10-22 Merus Nv Dominios de union mixtos.
CA3124688A1 (en) 2018-12-31 2020-07-09 Merus N.V. Truncated multivalent multimers
KR20230128134A (ko) 2019-01-22 2023-09-01 브리스톨-마이어스 스큅 컴퍼니 Il-7r 알파 서브유닛에 대한 항체 및 이의 용도
US20220127375A1 (en) 2019-02-14 2022-04-28 Merus N.V. Producing compositions comprising two or more antibodies
BR112021016094A2 (pt) 2019-02-14 2021-10-26 Merus N.V. Combinações de porções de ligação que se ligam ao egfr, her2 e her3
CA3125380A1 (en) 2019-02-18 2020-08-27 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals with humanized immunoglobulin locus
TW202039578A (zh) 2019-03-29 2020-11-01 荷蘭商美勒斯公司 Cd3結合分子
TW202102544A (zh) 2019-04-04 2021-01-16 日商小野藥品工業股份有限公司 雙特異性抗體
MA55884A (fr) 2019-05-09 2022-03-16 Merus Nv Domaines variants pour la multimérisation de protéines et leur séparation
CN114502725A (zh) * 2019-07-01 2022-05-13 特里安尼公司 转基因哺乳动物及使用方法
KR20220030956A (ko) 2019-07-05 2022-03-11 오노 야꾸힝 고교 가부시키가이샤 Pd-1/cd3 이중 특이성 단백질에 의한 혈액암 치료
CA3149309A1 (en) * 2019-07-30 2021-02-04 Ono Pharmaceutical Co., Ltd. Bispecific antibody
EP3772518A1 (de) 2019-08-07 2021-02-10 Merus N.V. Modifizierte menschliche variable domänen
AU2020331879A1 (en) 2019-08-19 2022-02-24 Merus N.V. Treatment of cancer with a combination of an antibody that binds LGR5 and EGFR and a topoisomerase I inhibitor.
GB201912008D0 (en) 2019-08-21 2019-10-02 Cambridge Entpr Ltd Antibody
CA3163549A1 (en) 2019-12-02 2021-06-10 Regeneron Pharmaceuticals, Inc. Peptide-mhc ii protein constructs and uses thereof
KR20220117267A (ko) 2019-12-24 2022-08-23 메뤼스 엔.페. Tgf-베타-rii 결합 단백질
IL294368A (en) 2020-01-29 2022-08-01 Merus Nv Means and method for modulating mixed effects in immune cells
JP2023523006A (ja) 2020-04-24 2023-06-01 メルス ナムローゼ フェンノートシャップ Ｌｇｒ５及びｅｇｆｒに結合する抗体によるがんの治療
KR20230018439A (ko) 2020-06-02 2023-02-07 바이오사이토젠 파마슈티컬스 (베이징) 컴퍼니 리미티드 공동 경쇄 면역글로불린 좌위를 갖는 유전자 변형 비인간 동물
KR20230066386A (ko) 2020-09-11 2023-05-15 리제너론 파마슈티칼스 인코포레이티드 항원 특이적 항체의 확인 및 제조
TW202237656A (zh) 2020-12-15 2022-10-01 荷蘭商美勒斯公司 利用結合ｌｇｒ５與ｅｇｆｒ之抗體治療癌症
WO2022132943A1 (en) 2020-12-16 2022-06-23 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
CN117603360A (zh) 2020-12-16 2024-02-27 美勒斯公司 用于治疗癌症的多特异性抗体
CA3202123A1 (en) 2020-12-18 2022-06-23 Alexander Berthold Hendrik Bakker Antibody composition
US20220195014A1 (en) 2020-12-23 2022-06-23 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding anchor modified antibodies and uses thereof
CA3237654A1 (en) 2021-10-06 2023-04-13 Merus N.V. Treatment of immune checkpoint inhibitor-treated cancers with high egfr expression using an antibody that binds at least egfr
WO2023146394A1 (en) 2022-01-25 2023-08-03 Merus N.V. Combination therapy for the treatment of cancer
WO2023172133A1 (en) 2022-03-07 2023-09-14 Merus N.V. Combination therapy including antibodies that bind egfr and cmet
WO2023172134A1 (en) 2022-03-07 2023-09-14 Merus N.V. Treatment with an antibody that binds egfr and cmet.
GB202216503D0 (en) 2022-11-05 2022-12-21 Quadrucept Bio Ltd Non-human vertebrates & cells
GB202217978D0 (en) 2022-11-30 2023-01-11 Petmedix Ltd Rodents expressing a common light chain
WO2024136658A1 (en) 2022-12-23 2024-06-27 Merus N.V. Combination treatment of cancers using an antibody that binds at least egfr and an immune checkpoint inhibitor
WO2024144401A1 (en) 2022-12-28 2024-07-04 Merus N.V. Treatment of cancer with a combination of an antibody that binds egfr and cytotoxic drugs

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4531078A (en) 1983-10-27 1985-07-23 Polaroid Corporation Control circuit for electronic flash
GB8909218D0 (en) 1989-04-22 1989-06-07 Medical Res Council Improvements in or relating to enhancers
US7041871B1 (en) * 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0814159B1 (de) * 1990-08-29 2005-07-27 GenPharm International, Inc. Transgene Mäuse fähig zur Produktion heterologer Antikörper
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2124967C (en) * 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
JPH08140528A (ja) * 1993-12-03 1996-06-04 Genpharm Internatl Inc 異種抗体を産生することができるトランスジェニック非ヒト動物
US5885827A (en) * 1996-01-23 1999-03-23 The Regents Of The Universtiy Of California Eukaryotic high rate mutagenesis system
EP0979281B1 (de) 1997-05-02 2005-07-20 Genentech, Inc. ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
DE69833755T2 (de) 1997-05-21 2006-12-28 Biovation Ltd. Verfahren zur herstellung von nicht-immunogenen proteinen
EP1068524A4 (de) * 1998-03-30 2005-01-26 Res Dev Foundation Corticotropin freisetzenden faktor rezeptor-1-defiziente mäuse
US20020028488A1 (en) * 2000-06-19 2002-03-07 Sujay Singh Transgenic avian species for making human and chimeric antibodies
US6596541B2 (en) * 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
PT1523496E (pt) * 2002-07-18 2011-09-29 Merus B V Produção de misturas de anticorpos de forma recombinante
EP1439234A1 (de) * 2003-01-08 2004-07-21 ARTEMIS Pharmaceuticals GmbH Gezielte Transgenese unter Verwendung des rosa26-Lokus
WO2004106375A1 (en) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
CA2554054C (en) 2004-01-20 2013-06-04 Merus B.V. Mixtures of binding proteins
JP4487068B2 (ja) * 2004-10-12 2010-06-23 国立大学法人 岡山大学 細胞の遺伝子変異機能の制御による変異タンパク質の作製方法
WO2006117699A2 (en) * 2005-04-29 2006-11-09 Innate Pharma Transgenic animals and methods of making recombinant antibodies
CA2638774C (en) * 2006-03-31 2015-11-24 Medarex, Inc. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
MY159787A (en) 2006-06-02 2017-01-31 Regeneron Pharma High affinity antibodies to human il-6 receptor
MX2009003393A (es) 2006-10-02 2009-05-11 Regeneron Pharma Anticuerpos humanos de alta afinidad para el receptor de il-4 humano.
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
KR20110029156A (ko) * 2008-06-27 2011-03-22 메뤼스 베.페. 항체 생산 비-인간 포유동물
NZ719253A (en) * 2010-02-08 2022-08-26 Regeneron Pharma Common light chain mouse

Also Published As

Publication number Publication date
KR102112655B1 (ko) 2020-05-19
CN102123582A (zh) 2011-07-13
JP7439201B2 (ja) 2024-02-27
JP2011525808A (ja) 2011-09-29
MX2010014542A (es) 2011-04-05
SI2147594T1 (sl) 2014-02-28
PT2556747T (pt) 2021-02-15
LT3456190T (lt) 2022-03-10
SG10201914027VA (en) 2020-03-30
KR20190025068A (ko) 2019-03-08
DK3456190T3 (da) 2022-02-14
CN105191863B (zh) 2020-12-22
RU2011102962A (ru) 2012-08-10
CA2729095A1 (en) 2009-12-30
HUE057994T2 (hu) 2022-06-28
JP2024063038A (ja) 2024-05-10
KR20200057093A (ko) 2020-05-25
JP2017121256A (ja) 2017-07-13
KR20170066688A (ko) 2017-06-14
JP6824807B2 (ja) 2021-02-03
JP2022188085A (ja) 2022-12-20
PL3456190T3 (pl) 2022-06-06
CY1114830T1 (el) 2016-12-14
EP2556747A3 (de) 2016-08-03
EP3456190A1 (de) 2019-03-20
KR101990228B1 (ko) 2019-06-17
ZA201009312B (en) 2011-08-31
EP2147594A1 (de) 2010-01-27
WO2009157771A3 (en) 2010-02-18
KR102306491B1 (ko) 2021-09-29
EP3456190B1 (de) 2021-11-24
EP2147594B1 (de) 2013-11-13
AU2009263082B2 (en) 2014-03-20
EP2556747B1 (de) 2020-12-02
HRP20140139T1 (hr) 2014-03-14
RS53146B (en) 2014-06-30
EP3456193A1 (de) 2019-03-20
HK1154463A1 (zh) 2012-04-27
RU2020127564A3 (de) 2022-02-21
RS62925B1 (sr) 2022-03-31
AU2009263082A1 (en) 2009-12-30
NZ590118A (en) 2012-10-26
CY1125119T1 (el) 2023-06-09
PL2147594T3 (pl) 2014-04-30
RU2731084C2 (ru) 2020-08-28
CN102123582B (zh) 2015-09-30
SI3456190T1 (sl) 2022-06-30
KR102261586B1 (ko) 2021-06-08
RU2015119670A (ru) 2015-12-10
KR20140127914A (ko) 2014-11-04
AU2009263082C1 (en) 2018-11-01
DK2556747T3 (da) 2021-02-15
JP7242611B2 (ja) 2023-03-20
WO2009157771A2 (en) 2009-12-30
CN112481300A (zh) 2021-03-12
EP3456191A1 (de) 2019-03-20
EP3456192A1 (de) 2019-03-20
PT2147594E (pt) 2014-02-17
ES2445193T3 (es) 2014-02-28
KR20110029156A (ko) 2011-03-22
ES2906344T3 (es) 2022-04-18
ES2853226T3 (es) 2021-09-15
JP2020191882A (ja) 2020-12-03
PT3456190T (pt) 2022-02-15
DK2147594T3 (da) 2014-02-10
JP2015156871A (ja) 2015-09-03
EP2556747A2 (de) 2013-02-13
CA2729095C (en) 2018-12-04
RU2559524C2 (ru) 2015-08-10
AU2009263082B9 (en) 2014-07-17
RU2015119670A3 (de) 2019-01-22
SG10201408500RA (en) 2015-01-29
HRP20220205T1 (hr) 2022-05-27
JP5749161B2 (ja) 2015-07-15
CN105191863A (zh) 2015-12-30
RU2020127564A (ru) 2022-02-21

Similar Documents

Publication Publication Date Title
HK1154463A1 (zh) 產生抗體的非人哺乳動物
EP2346994A4 (de) Nichtmenschliche säuger für die produktion chimärer antikörper
ZA201102119B (en) Improved antibody libraies
EP3064512C0 (de) Antikörper gegen cldn6
IL212701A0 (en) Improved anti-cd19 antibodies
HK1158229A1 (en) C-met antibodies c-met
SG10201403703XA (en) Methods of producing humanized non-human mammals
PL2262831T4 (pl) Przeciwciała przeciwko properdynie
GB0821100D0 (en) Antibodies
EP2337798A4 (de) Bsa-spezifische antikörper
EP2412808A4 (de) Bispezifischer lh-antikörper
ZA201006099B (en) Anti-tyrp1 antibodies
ZA201007976B (en) Anti-pirb antibodies
GB0818356D0 (en) Antibodies
GB0911770D0 (en) Antibody
FI20085308A0 (fi) Heparanaasittomia ihmiskuntaan kuulumattomia nisäkkäitä
GB0815963D0 (en) Antibody production
GB0820307D0 (en) Antibody production
PL384301A1 (pl) Urządzenie do produkcji biopaliwa
GB0819113D0 (en) An antibody
GB0817621D0 (en) Antibody
GB0817622D0 (en) Antibody
GB0804687D0 (en) Humanized antibody
GB0804686D0 (en) Humanized antibody
GB0804684D0 (en) Humanized antibody